2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
Open accessThe DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index; 152 of the 254 sources its claims cite were checked for support.
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
CoChat Summary
TL;DR
This ADA Standards of Care chapter provides updated recommendations for diagnosing and classifying diabetes, prediabetes, and related forms, including diagnostic thresholds, screening intervals, and classification categories. It emphasizes confirmatory testing, A1C limitations, risk-based screening, and special populations such as type 1 diabetes, gestational diabetes mellitus (GDM), cystic fibrosis–related diabetes (CFRD), posttransplantation diabetes mellitus (PTDM), pancreatic diabetes, and monogenic diabetes.
Key findings
- Diabetes diagnostic criteria: A1C ≥6.5% (≥48 mmol/mol), FPG ≥126 mg/dL (≥7.0 mmol/L), 2-h PG ≥200 mg/dL (≥11.1 mmol/L) during 75-g OGTT, or random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) with classic hyperglycemic symptoms/crisis; absent unequivocal hyperglycemia, diagnosis requires two abnormal results. Prediabetes is defined by A1C 5.7–6.4% (39–47 mmol/mol), FPG 100–125 mg/dL (5.6–6.9 mmol/L; IFG), or 2-h PG 140–199 mg/dL (7.8–11.0 mmol/L; IGT).
- Classification includes type 1 diabetes (5–10% of diabetes), type 2 diabetes (90–95%), specific types due to other causes, and GDM. Misdiagnosis is common and can occur in ~40% of adults with new type 1 diabetes; type 1 diabetes staging shows ~44% 5-year risk of symptomatic disease at stage 1 and ~60% risk by 2 years and ~75% within 5 years at stage 2.
- Screening: begin at age 35 years for all adults; consider earlier in adults with overweight/obesity plus one or more risk factors; repeat at minimum 3-year intervals if normal. In children/adolescents, consider risk-based screening after puberty or age 10 years, whichever is earlier, with overweight/obesity plus risk factors.
- Special populations: GDM screening at 24–28 weeks; one-step IADPSG criteria increase GDM diagnosis (e.g., 11.5% vs 4.9% in a 2021 USPSTF review) without demonstrated improved health outcomes. CFRD occurs in about 20% of adolescents and 40–50% of adults with cystic fibrosis; annual OGTT screening begins by age 10, and A1C is not recommended for screening due to low sensitivity. PTDM diagnosis is best made once stable on immunosuppression, usually at least 45 days after transplantation, with OGTT preferred. Monogenic diabetes accounts for <5% of diabetes; 80–85% of neonatal diabetes cases have a monogenic cause, and 30–50% of KATP-related neonatal diabetes improves with high-dose oral sulfonylureas.
Methods
- Design: ADA Standards of Care clinical practice guideline/consensus recommendations, updated annually by the ADA Professional Practice Committee, an interprofessional expert committee.
- Data/sample: No primary study sample; the chapter synthesizes published evidence and expert consensus. It references an ADA evidence-grading system (A/B/C/E) detailed in the Introduction and Methodology.
- Main analysis: Narrative synthesis of diagnostic, classification, and screening evidence with graded recommendations; no meta-analysis or primary data collection is reported in this chapter.
Limitations
- Stated evidence gaps include insufficient evidence for continuous glucose monitoring (CGM) for screening/diagnosis of prediabetes or diabetes; unknown optimal screening interval; uncertain benefit of treating early abnormal glucose metabolism; lack of randomized controlled trials for treating versus not treating GDM diagnosed by IADPSG but not Carpenter-Coustan criteria; and limited data on how treating maternal hyperglycemia affects offspring metabolic outcomes.
- Stated classification/diagnostic limitations include common misdiagnosis (e.g., ~40% of adults with new type 1 diabetes), poorly understood type 2 diabetes genetics, inadequate genetic data in diverse populations, and A1C unreliability in conditions such as hemoglobin variants, pregnancy, glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent blood loss/transfusion, or erythropoietin therapy.
- Evident from the text: this is a consensus guideline rather than a primary systematic review or meta-analysis; recommendations are graded A/B/C/E, with some based on expert consensus (E), and many cited studies are observational/cohort rather than randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 2.1 Flowchart for investigation of suspected type 1 diabetes in newly diagnosed adults, based on data from White European populations. 1 No single clinical feature con fi rms type 1 diabetes in isolation. 2 Glutamic acid decarboxylase (GAD) should be the primary antibody measured and, if negative, should be followed by islet tyrosine phosphatase 2 (IA-2) and/or zinc transporter 8 (ZnT8) where these tests are available. In individuals who have not been treated with insulin, antibodies against insulin may also be useful. In those diagnosed at < 35 years of age who have no clinical features of type 2 diabetes or monogenic diabetes, a negative result does not change the diagnosis of type 1 diabetes, since 5 -10% of people with type 1 diabetes do not have antibodies. 3 Monogenic diabetes is suggested by the presence of one or more of the following features: A1C < 58 mmol/mol ( < 7.5%) at diagnosis, one parent with diabetes, features of a speci fi c monogenic cause (e.g., renal cysts, partial lipodystrophy, maternally inherited deafness, and severe insulin resistance in the absence of obesity), and monogenic diabetes prediction model probability > 5% (diabetesgenes.org/exeter-diabetes-app/ModyCalculator). 4 A C-peptide test is only indicated in people receiving insulin treatment. A random sample (with concurrent glucose) within 5 h of eating can replace a formal C-peptide stimulation test in the context of classi fi cation. If the result is $ 600 pmol/L ( $ 1.8 ng/mL), the circumstances of testing do not matter. If the result is < 600 pmol/L ( < 1.8 ng/mL) and the concurrent glucose is < 4 mmol/L ( < 70 mg/dL) or the person may have been fasting, consider repeating the test. Results showing very low levels (e.g., < 80 pmol/L [ < 0.24 ng/mL]) do not need to be repeated. Where a person is insulin treated, C-peptide must be measured prior to insulin discontinuation to exclude severe insulin de fi ciency. Do not test C-peptide within 2 weeks of a hyperglycemic emergency. 5 Features of type 2 diabetes include increased BMI ( $ 25 kg/m 2 ), absence of weight loss, absence of ketoacidosis, and less marked hyperglycemia. Less discriminatory features include non-White ethnicity, family history, longer duration and milder severity of symptoms prior to presentation, features of the metabolic syndrome, and absence of a family history of autoimmunity. 6 If genetic testing does not con fi rm monogenic diabetes, the classi fi cation is unclear and a clinical decision should be made about treatment. 7 Type 2 diabetes should be strongly considered in older individuals. In some cases, investigation for pancreatic or other types of diabetes may be appropriate. 8 A person with possible type 1 diabetes who is not treated with insulin will require careful monitoring and education so that insulin can be rapidly initiated in the event of glycemic deterioration. 9 C-peptide values 200 -600 pmol/L (0.6 -1.8 ng/mL) are usually consistent with type 1 diabetes or maturity-onset diabetes of the young but may occur in insulin-treated type 2 diabetes, particularly in people with normal or low BMI or after long duration. Reprinted and adapted from Holt et al. (36).](https://figures.cochat.ai/paper-figures/7be96ed282694b1c85997763e16ae474/2-diagnosis-and-classification-of-diabetes-i-standards-of-care-in-diabetes2024-i-figure-1.png)

Verification
Claims the paper makes
99 Valid · 9 Not valid · 35 Not checked · 32 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However , in 2003 the ADA adopted the new range of 100 -125 mg/dL (5.6 -6.9 mmol/L) to better de fi ne IFG so that the population risk of developing diabetes with IFG would be similar to that with IGT (11).”
What the sources say
- Disputedcites [11] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 2003, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care sourceExperimental — accuracy not yet measured
In “The new criteria” (p. 8), the committee defines IFG as fasting plasma glucose of 110 to <126 mg/dL, not 100–125 mg/dL. The paper describes both IFG and IGT as risk factors for future diabetes, but it does not say the lower IFG threshold was adopted to make their population risks similar. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In most cases, such stressor steroidinduced hyperglycemia resolves by the time of discharge (142,143).”
What the sources say
- Partly supportedcites [142] Thomas, 2000, Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes, BMC Nephrol sourceExperimental — accuracy not yet measured
The Results (Hyperglycaemia; page unavailable) show that mean glucose fell from immediately after surgery to the morning of day 2. The Discussion (page unavailable) describes steroid exposure and postoperative hyperglycaemia, but the paper does not report whether most patients’ hyperglycaemia resolved by discharge. (LLM, conf=0.82)
- Disputedcites [143] Chakkera, 2009, Hyperglycemia during the immediate period after kidney transplantation, Clin J Am Soc Nephrol sourceExperimental — accuracy not yet measured
The Abstract (Results) says hyperglycemia was sustained throughout hospitalization and that 66% of patients without pretransplantation diabetes required insulin at discharge. The Discussion says the authors did not know what proportion would ultimately recover, rather than finding that most cases resolved by discharge. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Because periodontal disease is associated with diabetes, the utility of screening in a dental setting and referral to primary care as a means to improve the diagnosis of prediabetes and diabetes has been explored (108 -110)”
What the sources say
- Not checked — no full text of the sourcecites [108] Lalla, 2013, Dental findings and identification of undiagnosed hyperglycemia, J Dent Res source
- Not checked — no full text of the sourcecites [109] Lalla, 2011, Identification of unrecognized diabetes and pre-diabetes in a dental setting, J Dent Res source
- Supportedcites [110] Herman, 2015, Screening for prediabetes and type 2 diabetes in dental offices, J Public Health Dent source
The Discussion (page unavailable) describes periodontal disease and its sequelae as risk factors for dysglycemia, supporting the general association claimed. The paper’s own Results (page unavailable) found no association between clinical evidence of periodontitis and dysglycemia in its study sample, so it should not be cited as demonstrating that association in this cohort. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a community-based study of African American and non-Hispanic White adults without diabetes, baseline A1C was a stronger predictor of subsequent diabetes and cardiovascular events than fasting glucose (82).”
What the sources say
- Partly supportedcites [82] Selvin, 2010, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N Engl J Med sourceExperimental — accuracy not yet measured
The Abstract Conclusions state that glycated hemoglobin was more strongly associated than fasting glucose with cardiovascular disease risk, but only similarly associated with diabetes risk. The study population was community-based and included Black and White adults without diabetes. Page numbers are not provided in our copy. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The epidemiologic studies that formed the basis for recommending A1C to diagnose diabetes included only adult populations (112).”
What the sources say
- Could not verifycites [112] Cowie, 2010, Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006, Diabetes Care sourceExperimental — accuracy not yet measured
The introductory discussion (page unavailable) says an international expert committee recommended A1C for diagnosis, but does not give the ages of participants in the epidemiologic studies behind that recommendation. The Research Design and Methods section (page unavailable) includes participants aged 12 and older in this paper’s own analysis; that does not establish the ages in the studies the committee relied on. Searches for adult-only evidence and pediatric populations did not resolve the claim. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
74 more claims · 46 with their cited sources checked
Create a free account to see all 175 claims and to verify the 3 references still open.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 75
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HbA1c can be affected by some non-glycaemic factors, including anaemia due to iron deficiency or malaria, specific haemoglobin variants (eg, HbS and HbF), other haemoglobinopathies, polycythaemia due to living in high altitude, liver and kidney diseases, HIV, and specific drugs such as antiretroviral therapy for HIV.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many clinical guidelines recommend using a second confirmatory test for diabetes diagnosis and initiating treatment,6,21–23 although there is variation in this guidance.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measured
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Research works printed but not linked: 1
- International Diabetes Federation . IDF Diabetes Atlas, 10th edition. Brussels, Belgium, International Diabetes Federation, 2021. Accessed 26 September 2023. Available from https://www.diabetesatlas.org/atlas/tenth-edition/
Cited by
Items 301–400 of 2,029
Scilletta, S., Miano, N., Marco, M. D., Musmeci, M., Carasi, S., Capuccio, S., Pistritto, C., Ippolito, C., Tiralongo, M., Ricci, A., et al. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106511 · Cited by 9
He, J., Pan, X., Liu, D., Li, J., Li, Y., Wang, Y., Guo, J., Zhou, Q., Zhou, L. F., & Wang, L. (2025) · Journal of Global Health · doi:10.7189/jogh.15.04275 · Cited by 7
Balakrishnan, B., Hariharapura, R. C., Nayak, V., & Divyashree, M. S. (2025) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2025.2567336 · Cited by 8
“Hyperglycaemia, defined by the American Diabetes Association as a plasma glucose ≥ 200 mg/dl during an OGtt or random time of the day, or HbA1c ≥ 6.5%, is a key driver of molecular dysfunction in DbcM (committee, 2023).”
InfluentialDavoodian, N., Lotfaliany, M., Huxley, R., Lee, C., Pasco, J. A., Adams, R., Azizi, F., Bertoni, A. G., Colagiuri, S., Gregg, E. W., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06555-8 · Cited by 15
“…which is common in observational studies, we defined type 2 diabetes based on two abnormal FPG (FPG ≥7.0 mmol/l (126 mg/dl)) test results obtained at two different timepoints [29], self-reported type 2 diabetes, glucose-lowering medication use or type 2 diabetes diagnosis at previous timepoints.”
InfluentialVascular Aging, Cardiovascular-Kidney-Metabolic Syndrome, and Cardiovascular Risk
Shi, J., Ye, X., Yu, S., Zhao, Y., Xiong, J., Ji, H., & Zhang, Y. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102242 · Cited by 10
Chang, Y.-P., Chen, Y.-C., Cheng, P., Fang, Y., Chen, C.-Y., Kao, W., Lin, C., Yang, S.-S., Shih, Y. L., Peng, C., et al. (2026) · Gut · doi:10.1136/gutjnl-2025-337275 · Cited by 10
Trinks, N., Gancheva, S., Pützer, J., Schön, M., Huttasch, M., Pafili, K., Mastrototaro, L., Dewidar, B., Kupriyanova, Y., Herder, C., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2025.12.016 · Cited by 14
Association of Composite Metabolic Indices With Incident Carotid Plaque: A Chinese Cohort Study
He, Y., Xu, F., Deng, J., Li, M., & Leng, S. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047902 · Cited by 9
CEFALO, C. M. A., Riccio, A., Succurro, E., Marini, M. A., Fiorentino, T. V., Rubino, M., Perticone, M., Sciacqua, A., Andreozzi, F., & Sesti, G. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15646 · Cited by 11
Tong, X., Lyu, C., Guo, M., Gu, J., & Zhao, Y. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1383300 · Cited by 9
Latent autoimmune diabetes in adults: current data (review of literature and own data)
Pashkovska, N. V., & Tsaryk, I. (2024) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.20.3.2024.1384 · Cited by 10
Giannoulaki, P., Kotzakioulafi, E., Nakas, A., Kontoninas, Z., Karlafti, E., Evripidou, P., Kantartzis, K., Savopoulos, C. G., Chourdakis, M., & Didangelos, T. (2024) · Nutrients · doi:10.3390/nu16132089 · Cited by 9
“Chronic hyperglycemia in DMT-1 can lead to long-term damage and dysfunction in multiple organs, especially the eyes, kidneys, nerves, heart, and blood vessels [1].”
BackgroundLi, X., Liu, Y., Kang, S., Yang, D., Xiao, H.-Y., Ma, W., Shen, C., & Pan, J.-W. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02380-2 · Cited by 9
“Diabetes mellitus (DM) is a group of metabolic disorders that leads to the underutilization and overproduction of glucose [1].”
BackgroundMethodLin, Z., Song, Y., Yuan, S., He, J., & Dou, K. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15894 · Cited by 7
Influencing factors for postpartum depression in women with gestational diabetes mellitus
Tan, J., Xiong, Y., Wang, X., Wei, S.-Y., Luo, C., Huang, S., Yang, Y., Chen, J., Chen, J., Xu, M., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1423127 · Cited by 10
“The diagnosis of GDM was con fi rmed according to the GDM diagnosis criteria of China and the clinical practice recommendations of the American Diabetes Association (ADA) (13): the fasting plasma glucose (FPG) level ≥ 5.1 mmol/L (92 mg/ dL), or the one-hour postprandial plasma glucose (1hPG) level ≥ 10.0 mmol/L (180 mg…”
MethodInfluentialSong, J., McNeany, J., Wang, Y., Daley, T. C., Stecenko, A. A., & Kamaleswaran, R. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.109255 · Cited by 8
Tavares, W. R., Seca, A. M. L., & Barreto, M. D. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14031028 · Cited by 11
da Cruz, L. L., Sinzato, Y. K., Paula, V. G., Fioretto, M. N., Gallego, F. Q., Barco, V. S., Camargo, A. C. L., Corrente, J. E., Justulin, L. A., Rodrigues, T., et al. (2025) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s204017442400045x · Cited by 7
Diabetes Mellitus Risk Prediction in the Framingham Offspring Study and Large Population Analysis
Ai, M., Otokozawa, S., Liu, C., Asztalos, B. F., Maddalena, J., Diffenderfer, M. R., Russo, G. T., Thongtang, N., & Dansinger, M. L. (2025) · Nutrients · doi:10.3390/nu17071117 · Cited by 9
“This is also the case if you are a 65-year-old woman and are obese [1].”
InfluentialKim, S., Hwang, J., Yon, D. K., Sang, H., Woo, S., Woo, H. G., Lim, H. J., Park, J., Hsiao, F., Chen, L., et al. (2025) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70028 · Cited by 9
“Recent evidence suggests that glucose variability, particularly HbA1c variability score (HVS), could independently predict adverse cardiovascular outcomes [3–5].”
Mallone, R., Bismuth, É., Thivolet, C., Benhamou, P., Hoffmeister, N., Collet, F., Nicolino, M. P., Reynaud, R., Beltrand, J., Beltrand, J., et al. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.06.003 · Cited by 11
“La maladie peut être détec-tée précocement et classée selon des stades précliniques définis [20,21].”
Risk and factors determining diabetes after mild, nonnecrotizing acute pancreatitis
Pichardo-Lowden, A. R., Goodarzi, M. O., Trikudanathan, G., Serrano, J., & Dungan, K. M. (2024) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001055 · Cited by 11
Putranto, R., Setiati, S., Nasrun, M. W. S., Witjaksono, F., Immanuel, S., Subekti, I., Harimurti, K., Siswanto, A., Shatri, H., Suwarto, S., et al. (2024) · Narra J · doi:10.52225/narra.v4i3.1342 · Cited by 7
Alarcon, G., Nguyen, A. M., Jones, A. G., Shields, B. M., REDONDO, M. J., & Tosur, M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae770 · Cited by 7
Harnois‐Leblanc, S., & Hivert, M. (2024) · Diabetes · doi:10.2337/dbi24-0014 · Cited by 7
Rohlfing, C. L., Petroski, G. F., Connolly, S. M., Hanson, S. E., Little, R. R., & Kabytaev, K. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2024-1260 · Cited by 8
Fecal Short-Chain Fatty Acids Are Associated with Obesity in Gestational Diabetes
Molan, K., Avguštin, J. A., Likar, M., Barlovič, D. P., Barlovič, D. P., & Erjavec, M. S. (2025) · Biomedicines · doi:10.3390/biomedicines13020387 · Cited by 8
“Gestational diabetes mellitus (GDM) is defined as any glucose intolerance that first appears in pregnancy [25].”
Martin, A., Lang, S., Schifferdecker, F., Allo, G., Chon, S., Neumann‐Haefelin, C., Demir, M., Steffen, H., & Kasper, P. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000003977 · Cited by 7
“…from 10 : 01 p.m. till 05 : 59 Hypertension phenotypes were defined according to the latest ESH guideline [8]: The following terms describe the hypertension phenotypes of patients without antihypertensive treatment: true < þ BP < 135/85 mmHg þ meannight-timeBP < sustained hypertension (SH) (OBP…”
Lakhani, H. A., Biswas, D., Kuruvila, M., Chava, M. S., Raj, K., Varghese, J. T., & Swathi, N. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.02.006 · Cited by 7
Trending Modalities in Type 2 Diabetes Prevention
Lundgrin, E. L., & Hatipoğlu, B. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf040 · Cited by 8
Taschereau, A., Doyon, M., Arguin, M., Allard, C., Desgagné, V., Côté, A., Massé, É., Jacques, P., Perron, P., Hivert, M., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-093434 · Cited by 8
Richardson, K. M., Schembre, S. M., Jospe, M. R., Widmer, A., & Silver, H. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16395 · Cited by 13
Martin, A., Rosa, G. R. M. L., Rice, H., Bertuzzi, A., Witkowski, M., Anastasi, E., Geraci, G., Polosa, R., Campagna, D., Ciaula, A. D., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112202 · Cited by 6
Role of exosomes in pathogenesis, diagnosis, and treatment of diabetic nephropathy
Barr, S. I., El-Azeem, E. M. A., Bessa, S. S. E.-D., & Mohamed, T. M. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04120-4 · Cited by 10
Zhang, Z., Chen, H., Chen, L., Liang, W., Hu, T., Sun, N., Zhao, Y., & Wei, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-87277-0 · Cited by 9
Martinenghi, S., Merolla, A., Grogan, P., Bianconi, E., Senni, E., Goncharova, A., Massara, F., Ragogna, F., Bazzigaluppi, E., Pastore, M. R., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06461-z · Cited by 14
A comparison of current methods to measure antibodies in type 1 diabetes
Infantino, M., Manfredi, M., Garrafa, E., Pancani, S., Lechiara, A., Mobilia, E. M., Grossi, V., Lari, B., Bizzaro, N., & Pesce, G. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-0238 · Cited by 7
Washirasaksiri, C., Borrisut, N., Lapinee, V., Sitasuwan, T., Tinmanee, R., Kositamongkol, C., Ariyakunaphan, P., Tangjittipokin, W., Plengvidhya, N., & Srivanichakorn, W. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004803 · Cited by 8
da Silva, B. R., Hidalgo, M. A. R., Silva, R. C. L., de Ávila, É. D., Fuentes, D. L. P., Carlos, I. Z., Figueiredo, I. D., Cerri, E. S., Cerri, P. S., Baviera, A. M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125611 · Cited by 6
Chen, H., Miao, X., Hu, M., Song, Z., He, Y., Deng, J., & Leng, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1585811 · Cited by 6
Glycemic control and asymptomatic carotid plaque and carotid intima–media thickness
Zhang, J., Song, X., Zhang, G., et al. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004786 · Cited by 6
“19 In the diabetes group, adhering to the recommended glycemic targets for older adults by the American Diabetes Association Professional Practice Committee, 20 we further classified the diabetes group into subgroups: the well-controlled group (HbA1c 7.5”
InfluentialIncretin system and glucagon secretion in patients with chronic pancreatitis
Ciccarelli, G., Giuseppe, G. D., Gliozzo, G., Soldovieri, L., Quero, G., Nista, E. C., Brunetti, M., Cinti, F., Lucia, S. S. D., Hartmann, B., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70093 · Cited by 6
Patro, S., Sharma, V., Choudhary, A., Varuneil, Y., Arora, P., Nayak, S., & Sahoo, J. P. (2025) · Cureus · doi:10.7759/cureus.87759 · Cited by 9
“We included adult patients (of either gender) diagnosed with T2DM per the American Diabetes Association (ADA) criteria [15].”
Huang, K., Ma, L., Shi, S., Wang, X., Jiang, S., & Zhang, Y. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70074 · Cited by 6
“…this study meets the diagnostic criteria for type 2 diabetes mellitus (T2DM) as outlined in the 2024 American Diabetes Association (ADA) guidelines 13,14 ; (2) onset age is de fi ned as 40 years or younger; (3) a BMI ranging from 24.0 to 27.9 kg/m 2 is indicated; and (4) these patients did not…”
InfluentialLiao, Y., Han, Y. Y., Cao, C., Song, H., & Hu, H. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01907-1 · Cited by 6
“The detailed process of defining prediabetes is described as follows: Diabetes was defined as FPG ≥ 7.0 mmol/L, hemoglobin A1c (HbA1c) ≥ 6.5%, or self-reported diabetes during follow-up[25].”
InfluentialLuo, Y., Li, X., Yang, T., Zhou, K., Wang, T., Zhang, Y., Huang, J., Hu, C., Li, J., Zhao, Q., et al. (2025) · BMC Public Health · doi:10.1186/s12889-025-24491-5 · Cited by 15
Liang, J., Liang, Y., Chen, L., Cai, M., Li, S., He, L., Xu, Y., Tan, Y., Li, L., Wu, X., et al. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1675899 · Cited by 9
Sigera, S., Theekshana, K. D., Dinanja, S. G., Eranga, P., Karunathilake, N., Abeywardhana, S., Weerasinghe, L., Senapathi, T., & Peiris, L. D. C. (2025) · Marine Drugs · doi:10.3390/md23120471 · Cited by 9
“Recent data indicate that 23% of adults in Sri Lanka have diabetes, while an additional 30.5% are in a pre-diabetic state, reflecting the higher prevalence in South Asia and imposing a significant economic burden [5,6].”
InfluentialRecent advances and ongoing challenges in diabetes prevention and control in China
Geng, T., Yin, X., Guo, Y., Liu, G., Pan, A., & Liao, Y. (2025) · The Innovation · doi:10.1016/j.xinn.2025.101083 · Cited by 12
“28 In China, its burden is substantial.”
Engineering smart bacteria for the next generation
Qiao, L., Wang, Z., Tang, S., Tian, J., Ye, H., & Cai, F. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102681 · Cited by 12
Zhang, Y., & Wang, D. D. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2644682 · Cited by 13
Alemán-Contreras, R., Gómez-Díaz, R. A., Noyola-García, M. E., Mondragón-González, R., Wacher, N. H., & Ferreira‐Hermosillo, A. (2024) · Life · doi:10.3390/life14050550 · Cited by 14
“…that attended at least three visits in the last year, aged 18–70 years, with previous clinical diagnosis of T1D, T2D, or MODY, classified according to the standards of the American Diabetes Association (ADA) [10], or with LADA, according to the criteria of the Immunology of Diabetes Society [2].”
MethodNeubauer‐Geryk, J., Wielicka, M., Hoffmann, M., Myśliwiec, M., & Bieniaszewski, L. (2024) · Biomedicines · doi:10.3390/biomedicines12051020 · Cited by 7
“Diabetic nephropathy was diagnosed based on the current determination of albumin levels in a collected urine sample and albuminuria tests during the last 6 months before the study.”
BackgroundZhang, Y., Geng, C., Zhou, Y., Li, F., Peng, S.-L., Guo, X., Gu, X., Li, J., & Li, H. Z. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s460605 · Cited by 6
Clinical Features and HLA Genetics Differ in Children at Type 1 Diabetes Onset by Hispanic Ethnicity
Karakus, K. E., Fleury, T., Baschal, E. E., McDaniel, K. A., Choi, H., Armstrong, T., Yu, L., Simmons, K. M., & Michels, A. W. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae608 · Cited by 7
Identifying the Genetic Associations Between Diabetes Mellitus and the Risk of Vitiligo
Zhao, L., Hu, M., & Li, L. (2024) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s480199 · Cited by 8
Amador-Gómez, A. I., Aguíñiga-Sánchez, I., Mendoza-Núñez, V. M., Cadena-Íñiguez, J., Romero-López, E., & Santiago‐Osorio, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111477 · Cited by 6
“Research has explored metformin use”
ResultLiepert, M., Alhaqqan, S., Husain, A., Lochnan, H. A., Booth, R. A., Shaw, J. L. V., & Sun, C. (2024) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2024.110842 · Cited by 7
Won, K., Choi, S., Chun, E. J., Park, S. H., Sung, J., Jung, H. O., & Chang, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-80324-2 · Cited by 7
Zhang, M., Ye, S., Li, J., Zhang, M., Tan, L., Wang, Y., Xie, P., Peng, H., Li, S., Chen, S., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1399832 · Cited by 7
Comparing medication persistence with oral and subcutaneous semaglutide in a real-world setting
Conti, M., Pontiggia, L., Vergani, M., Muraca, E., Cannistraci, R., Perra, S., Lattuada, G., Perseghin, G., & Ciardullo, S. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02424-9 · Cited by 12
“Type 2 diabetes mellitus (T2DM) is a complex disease with a high prevalence and steadily increasing incidence world-wide [1].”
Doğan, Z., Şenyiğit, A., Durmuş, S., Duvarcı, C., Gelışgen, R., Uzun, H., & Tabak, Ö. (2025) · Scientific Reports · doi:10.1038/s41598-025-89220-9 · Cited by 10
Kudva, Y. C., Henderson, R. J., Kanapka, L. G., Weinstock, R. S., Rickels, M. R., Pratley, R. E., Chaytor, N., Janess, K., Desjardins, D., Pattan, V., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0560 · Cited by 7
Self-citationUddin, S., Machado, M. S., Alshahrouri, B., Echeverri, J. I., Rico, M. C., Rao, A. D., Ruchalski, C., & Barrero, C. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113822 · Cited by 15
“Tests used for diagnosis include (1) random or fasting plasma glucose (FPG), (2) the oral glucose tolerance test (OGTT), a 2 h plasma glucose (2 h PG) value after 75 g oral glucose consumption, and (3) the hemoglobin A1C (HbA1C) test [1,20].”
InfluentialHao, Y., Wu, B., Feng, J., et al. (2025) · International Ophthalmology · doi:10.1007/s10792-025-03636-w · Cited by 6
Xu, X., He, M., Zhao, G., Liu, X., Liu, X., Xu, H., Cheng, Y.-P., Jiang, Y., Peng, Q., Shi, J., et al. (2024) · Nutrients · doi:10.3390/nu16172968 · Cited by 7
“The definition of diabetes was glycosylated hemoglobin type A1C (HbA1C) ≥ 6.5% ( ≥ 48 mmol/mol), fasting blood glucose (FPG) ≥ 126 mg/dL ( ≥ 7.0 mmol/L), or prior diagnosis of diabetes [42].”
BackgroundInfluentialZhang, F., & Li, W. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1492647 · Cited by 6
Huang, L., Li, X., Zou, M., Zeng, H., Wu, S., Liang, Y., Wang, D., Yang, Y., Qiu, Z., & Zhou, Q. (2025) · Food & Function · doi:10.1039/d4fo04557b · Cited by 7
Fischer, A., Remde, H., Pamporaki, C., Dischinger, U., Bechmann, N., Robledo, M., Wang, K., Vetter, D., Oberholzer, J., Morand, G. B., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae901 · Cited by 10
Sasaki, N., Ueno, Y., Ozono, R., Nakano, Y., & Higashi, Y. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16307 · Cited by 6
Zhao, C., Zhao, L., Liu, Y., et al. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1569798 · Cited by 5
Hsiang, C., Lo, H., & Ho, T. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143531 · Cited by 5
Jia, F., Lu, Y., Wen, H., Tu, J., Ning, X., Wang, J., & Li, P. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s505024 · Cited by 6
Swaby, R., Narayan, K., Scudder, C. L., Townson, J. K., Oram, R. A., Bell, K. J., Craig, M. E., Dayan, C. M., Aveyard, P. N., & Besser, R. E. J. (2025) · Diabetic Medicine · doi:10.1111/dme.70077 · Cited by 8
Psychometric properties of the EQ-5D-5L in diabetes mellitus patients in Spain
Bilbao‐González, A., de Tejada, M. G., Ferrer, M., Ramallo‐Fariña, Y., Paja-Fano, M., Forero, C. G., Mestre, D., & Gorostiza, I. (2025) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-025-00874-5 · Cited by 7
“Diabetes mellitus (DM) is one of the most important public health problems worldwide due to its high prevalence, morbidity, influence on patients’ health related quality of life (HRQOL) and impact on the healthcare system [1].”
Akbari, M. R., Masjedi, F., Nekooeian, M., Dara, M., & Roozbeh, J. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70071 · Cited by 7
“Diabetes mellitus (DM) is a chronic metabolic disorder characterized by elevated blood glucose levels, resulting from either insuf fi cient insulin production or insulin resistance 24 .”
Common Tongue Manifestations in Patients with Diabetes and Hypertension
Al-Hajjar, S. H. A., Alhusseini, N. B., Annooz, T. S., Khalel, A. M., & Ibrahim, S. M. (2025) · The Open Public Health Journal · doi:10.2174/0118749445402607250619104329 · Cited by 6
DNA sequence classification for diabetes mellitus using NuSVC and XGBoost: A comparative
Salloum, S. A., Alomari, K. M., & Salloum, A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0328253 · Cited by 5
“Traditionally, the diagnosis of diabetes has relied on clinical measures such as fasting blood glucose levels, HbA1c (glycated hemoglobin), and oral glucose tolerance tests [2].”
Impact of Micro-RNAs as biomarkers for end-stage renal disease related to hypertension and diabetes
Ata, A., Ezzat, D., Sherkawy, H. S., Ahmed, A. E., Afify, M., Abdelmaksoud, M. D. E., Azazy, S., & Gouda, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-16013-5 · Cited by 9
Obesity and Pregnancy: Impact on Childbirth Timing, Delivery Mode, and Maternal Recovery: An Update
Gerede, A., Danavasi, M., Stavros, S., Potiris, A., Zikopoulos, A., Moustakli, E., Skentou, C., Domali, E., Nikolettos, N., & Eleftheriades, M. I. (2025) · Medical Sciences · doi:10.3390/medsci13030182 · Cited by 24
“Our review supports the following: (a) universal early GDM screening (<20 weeks) for pregnant women who are obese at the practice level [99]; (b) women with a BMI ≥ 40 and other risk factors may be given consideration for a planned cesarean delivery [84]; (c) giving high-risk obese women extended…”
Puig, R., Rojo-López, M. I., Julve, J., Castelblanco, E., Ponomarenko, J. V., Amézqueta, S., Vendrell, J. J., Franch‐Nadal, J., Torres, J. L., Mauricio, D., et al. (2025) · Nutrients · doi:10.3390/nu17183003 · Cited by 6
Predictive performance of traditional and novel anthropometric indices for diabetes and hypertension
Pezeshki, M., Esmaeili, S., Mahdavi‐Gorabi, A., Sadegi, T., Kiaee, Z. F., Assar, O., Semnani, K., & Qorbani, M. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70172 · Cited by 6
“We found anthropometric indices to be poor predictors of current status regarding IFG and elevated blood pressure in both sexes.”
InfluentialProgress in nasal drug delivery research based on biomaterials
Qiu, H., Duan, X., Su, Y., Zeng, S., Zheng, D., & Liao, W. (2025) · APL Materials · doi:10.1063/5.0296863 · Cited by 5
Autoimmune Type 1 Diabetes in the Era of Disease‐Modifying Immune Therapy
Michels, A. W., Gottlieb, P. A., Nelson, B., & Dayan, C. M. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70091 · Cited by 7
“Stage 2 is defined by the presence of 2 or more islet autoantibodies and the development of impaired glucose tolerance (dysglycemia) [21, 33].”
He, X., Lu, Z., Guo, Y.-F., Zhao, R., & Liu, Z. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1632400 · Cited by 7
Nghiem, T. P., Tran, H. M., Nguyen, D. N. Q., Dao, L. T., Tran, C. C., & Tuan, V. M. (2025) · Medical Sciences · doi:10.3390/medsci13040237 · Cited by 9
“Adults aged ≥ 18 years with a confirmed diagnosis of T2DM (based on ADA 2024 criteria) [13], in sinus rhythm, and with preserved LVEF ( ≥ 50”
Wang, H., Zhang, H., Zhang, L., Zheng, X., & Yang, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-21850-5 · Cited by 7
Aniagyei, W., Sarfo‐Kantanka, O., Mohayideen, S., Vivekanandan, M. M., Adankwah, E., Asibey, S. O., Boateng, A. O., Owusu, E., Arthur, J. F., Yeboah, A., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06576-3 · Cited by 8
“Diagnosis of diabetes followed the ADA criteria [17] and classification as type 1 diabetes was based on clinical symptoms suggestive of insulin deficiency such as polyuria, polydipsia, weight loss, ketonaemia/ketonuria or marked hyperglycaemia non-responsive to oral glucose-lowering drugs.”
InfluentialAssessment of AOPP, TBARS, and Inflammatory Status in Diabetic Nephropathy and Hemodialyzed Patients
Caragea, D. C., Boldeanu, L., Assani, M.-Z., Caragea, M.-E., Stroe-Ionescu, A.-Ş., Popa, R., Maria, D. T., Pădureanu, V., Vere, C. C., & Boldeanu, M. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110670 · Cited by 7
Current treatment for diabetes: a holistic approach
Mourelatou, N. G., Kounatidis, D. C., Vallianou, N. G., Daniele, G., Dardano, A., & Rebelos, E. (2025) · HORMONES · doi:10.1007/s42000-025-00734-3 · Cited by 8
“Although LADA is not officially recognized as a separate diabetes type and is generally considered a form of T1D, its management requires a distinct and individualized approach [101].”
Beneficial effects of berberine in the treatment of diabetes and its complications
Liu, S., Shen, J., Xu, F., Niu, L., Wang, F., & Zhao, G. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1701513 · Cited by 7
New Treatment Options for MASLD Patients with Type 2 Diabetes
Mega, A., Turri, C., Marzi, L., Dauriz, M., Sacco, R., Floreani, A., & Stasi, C. (2026) · Life · doi:10.3390/life16020254 · Cited by 12
“…in combination with lifestyle interventions, and tailored to comorbid conditions, safety profiles, and patient preferences, international guidelines [15,16,35] emphasize prioritizing GLP-1RA and SGLT2i in MASLD patients with T2DM or obesity, due to their dual metabolic and hepatic benefits.”
InfluentialA treat‐to‐target approach for obesity management: A post hoc analysis of the SURMOUNT ‐5 trial
le Roux, C. W., Busetto, L., Aronne, L. J., Horn, D. B., Dimitriadis, G. K., Falcón, B. L., García‐Pérez, L., Valderas, E. G., Gibble, T. H., Şenyücel, Ç., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70531 · Cited by 5
Talbot, S. R., Heider, M., Wirth, M., Jörns, A., & Naujok, O. (2026) · Scientific Reports · doi:10.1038/s41598-026-42408-z · Cited by 8
“However, the threshold value for a DM diagnosis is significantly lower at only 11.1 mmol/L random plasma glucose 38 .”
InfluentialLiang, G., Lai, M., Wang, Y., Li, N., Kang, M., Lu, J., Su, Y., Fang, F., Peng, Y., Xu, X., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15698 · Cited by 5
Association of remnant cholesterol with coronary artery ectasia: a cross-sectional study
Mu, J., Weng, Y., Xiao, J., et al. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02225-7 · Cited by 5
“Diabetes mellitus was defined as a fasting glucose level ≥ 126 mg/dL, a nonfasting glucose level ≥ 200 mg/dL, a self-reported diagnosis of diabetes mellitus, or a history of using hypoglycemic medications [16].”
BackgroundRuiz‐García, A., Serrano-Cumplido, A., Escobar, C., Arranz-Martínez, E., & Pallarés‐Carratalá, V. (2024) · Medicina · doi:10.3390/medicina60081309 · Cited by 5
Billings, L. K., Shi, Z., Mulford, A. J., Wei, J., Tran, H. M., Ashworth, A., Zheng, S. L., Dunnenberger, H. M., Hulick, P. J., Sanders, A. R., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14297 · Cited by 6
Hoffmeister, M. C., Lovison, V. H., Friedrich, E. P., & Rodrigues, T. D. C. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111873 · Cited by 5
Wu, Y.-R., Su, W.-S., Lin, K., & Lin, I. (2024) · Applied Psychophysiology and Biofeedback · doi:10.1007/s10484-024-09666-x · Cited by 6
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., Seley, J. J., Selvin, E., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Bannuru, Raveendhara R.
- Bruemmer, Dennis
- Collins, Billy S.
- Ekhlaspour, Laya
- Gaglia, Jason L.
- Hilliard, Marisa E.
- Johnson, Eric L.
- Khunti, Kamlesh
- Lingvay, Ildiko
- McCoy, Rozalina G.
- Perry, Mary Lou
- Pilla, Scott J.
- Polsky, Sarit
- Prahalad, Priya
- Pratley, Richard E.
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Selvin, Elizabeth
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-11
- Volume
- 47
- Issue
- Supplement_1
- Pages
- S20-S42
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC10725812
- OpenAlex
- W4389560718
- Cited by
- 2,086
- References
- 232
- Citations by year
- 2026: 771 · 2025: 903 · 2024: 408 · 2023: 1
- FWCI
- 74.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- diabetes diagnosis, diabetes classification, diabetes mellitus, clinical guidelines, American Diabetes Association standards of care, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.